www-com-develops-35.html
Novo Annual Report 2015
36 / 72
public
com
panies colucid pharmaceuticals (nasdaq
:clcd) develops innovative therapies for cns disorders. the lead programme is in phase 3 clinical development for the treatment of migraine. www
.colucid.com glaukos (nasdaq:gkos) is an ophthalmic medical technology company focused on the development and commercialisation of break-through products and procedures to transform the treatment of glaucoma, the second-leading cause of blindness. www.glaukos.com htg molecular diagnostics (nasdaq:htgm) develops and sells its edge instrument and assays for quantification of gene expression. the instrument and assays are used for clinical diagnostics and in research. the edge instrument is being launched in the us. www.htgmolecular.com invuity (nasdaq:ivty) is a commercial-stage medical technology company pioneering the use of advanced photonics to provide surgeons with improved direct visualisation of surgical cavities during minimally invasive and minimal access surgical procedures. www.invuity.com nabriva therapeutics (nasdaq:nbrv) is focused on the research and development of novel anti- infective agents to treat serious infections. the lead product candidate, lefamulin, is entering phase 3 clinical development for the treatment of moderate to severe community-acquired bacterial pneumonia. www.nabriva.com ophthotech (nasdaq:opht) is a biopharmaceutical company specialising in the development of novel therapeutics to treat diseases of the eye. the company has initiated a pivotal phase 3 clinical programme for its most advanced product candidate, fovista? anti-pdgf therapy. www.ophthotech.com penumbra (nyse:pen) is a therapy company that designs, develops, manufactures and commercialises innovative medical devices primarily for the neuro and peripheral vascular markets. www.penumbrainc.com tobira therapeutics (nasdaq:tbra) develops products for the treatment of non-alcoholic steatohepatitis (nash) and hiv. the lead compound, a ccr5 antagonist for the treatment of hiv infection, is in a phase 2b study for nash and has completed phase 2b clinical development in hiv. www.tobiratherapeutics.com tokai pharmaceuticals (nasdaq:tkai) develops novel therapies for prostate cancer and other hormonally driven diseases. the lead candidate, galeterone is in phase 3 clinical development for the treatment of castration-resistant prostate cancer. www.tokaipharmaceuticals.com xenon pharmaceuticals (nasdaq:xene) is a genetics-based drug development company. the company?s lead compound is in clinical development for the treatment of pain. www.xenon-pharma.com novo ventures novo a/s 36
acquired-sold-shares-37.html
